Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?

Mark Lappe, Chief Executive Officer, purchased 25,000 shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX) on September 8, 2026. SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average purchase price ($105.82); post-transaction value based on September 08, 2026 market close ($114.34).

Key questions

• What was the execution strategy for this acquisition?
  The CEO purchased the shares through multiple transactions at prices ranging from $98.88 to $112.44 per share, resulting in a weighted average cost basis of $105.82.
• Which entities now hold the CEO's equity position?
  The total position is held entirely through indirect entities, including 730,548 shares in the Lappe Family Trust, 165,000 shares in a trust for family beneficiaries, and 54,865 shares in the Mark Paul Lappe Roth IRA.
• How does this move impact the CEO's total beneficial ownership?
  The transaction increased the CEO's total beneficial ownership to ~950,000 shares, which represents approximately 6% of the company's outstanding equity.
• What is the company's current financial profile in the context of this buy?
  Inhibrx Biosciences, a clinical-stage biotechnology firm based in La Jolla, California, reported a trailing twelve-month net loss of $138.2 million and maintains a market capitalization of $1.4 billion as of the Sept. 8, 2026 market close.

Company Overview

Company Snapshot

• Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of novel biologic therapeutic candidates utilizing proprietary modular protein engineering platforms, with lead candidates INBRX-109 and INBRX-106 employing optimized multivalent formats for targeted agonist function.
• The company operates a development-stage business model focused on advancing clinical-stage therapeutic candidates through regulatory pathways, with revenue generation dependent upon successful clinical development, regulatory approval, and eventual commercialization of its biologic therapeutics.
• Inhibrx targets pharmaceutical and biotechnology partners, healthcare providers, and patient populations suffering from diseases amenable to treatment with its engineered biologic therapeutic candidates across multiple therapeutic areas.

Inhibrx Biosciences represents a clinical-stage biopharmaceutical enterprise with a market capitalization of $1.40 billion, leveraging proprietary modular protein engineering platforms to develop novel biologic therapeutics. The company's competitive positioning is derived from its differentiated platform technology enabling precise optimization of therapeutic valency and agonist function, with a focused clinical pipeline advancing toward potential regulatory milestones. As a pre-revenue clinical-stage company, Inhibrx's financial profile reflects typical biotechnology development-stage dynamics, with operating losses offset by investor confidence in its platform technology and clinical pipeline potential.

What this transaction means for investors

There are multiple reasons a company insider may sell shares in the business. One reason could be the need to raise cash to meet a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company's future.

However, there is only one reason an insider buys stock: they believe the share price is going up.

By that investor's rule of thumb, Lappe's purchase of $2.6 million worth of Inhibrx shares is bullish. Adding to the bullishness is the fact that studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.

Lappe founded Inhibrx in 2010 and has been the company's CEO ever since. He knows the business inside and out.

Trials for the companies various treatments are proceeding well. Earlier this month, the company announced positive trials response rates for its INBRX-106 treatment.

"What is most exciting to us is the depth and durability of the responses we are seeing with INBRX-106, particularly in HPV+ disease," said Lappe in a press release put out by the company. "These results strengthen our conviction in OX40-mediated T-cell costimulation and give us a strong rationale to expand the program, not only into HPV+ disease, but also to explore the potential of INBRX-106 in other highly immunogenic tumors and in combination with cancer vaccines."

There are no guarantees with a development stage biotech, but the positive results and Lappe's buying suggests he believes strongly in what the future holds for the business.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.